1 week Ago By By Nanoscope Therapeutics
Presentations to highlight efficacy, durability, and safety of Nanoscope's optogenetic therapy platforms DALLAS , April 25, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope's presentations will be centered around 126-week outcomes following treatment with its MCO-010 optogenetic therapy for retinitis pigmentosa (RP), the first and only therapy shown to restore vision in advanced RP patients via a one-time, standard intravitreal injection.
"We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and look forward to sharing more about the positive therapeutic benefits seen in RP patients treated with our multi-characteristic opsin, or MCO, therapy," said Dr. Samarendra Mohanty , co-founder and President of Nanoscope. "Multi-year benefit is meaningful for patients looking for a one-time, durable treatment option for their irreversible, progressive vision loss due to RP, and it underscores the potential of MCO-010 to redefine the standard of care.
It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, including BLA submission." Details of the presentations are as follows: Eyecelerator | Ophthalmic Innovation Conference Friday, May 2 nd , 2025 Grand Hyatt Deer Valley , Park City, UT Nanoscope participation: ARVO, The Association for Research in Vision and Ophthalmology Sunday, May 4 th to Thursday, May 8 th , 2025 Salt Palace Convention Center, Salt Lake City, UT Nanoscope presentations: Nanoscope team members will be available at Booth 1337 for the duration of the ARVO conference. About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP ( NCT04945772 ), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients ( NCT05417126 ) and plans to initiate a Phase 3 registrational trial , also in 2025.
MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies. Investor Contact: Argot Partners 212-600-1902 PR@nanostherapeutics.
com View original content to download multimedia: https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2025-annual-meetings-302438729.
html SOURCE Nanoscope Therapeutics.
